poisar

Stock

Moleculin Biotech, Inc. MBRX

$0.57+9.40%

Overview

MBRX market data

Price History

MBRX price chart

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$28.33
Diluted earnings per share over the trailing twelve months.
Beta
1.95
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$0.16 – $17.38
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $3.2M · P/B 0.46.

Company News

10 captured
Moleculin Biotech Q2 EPS $(1.40) Misses $(1.01) EstimateBenzinga · Aug 14, 2026, 12:48 PM
8-K filing — Moleculin Biotech, Inc. (MBRX)SEC EDGAR · Aug 14, 2026, 12:30 PM
Moleculin Biotech Stock Is Sinking Friday: What's Going On?Benzinga · Jul 31, 2026, 5:37 PM
Moleculin Biotech shares are trading lower after the company announced it priced a $9.3 million public offering.Benzinga · Jul 31, 2026, 4:48 PM
Moleculin Biotech Announces Its Miracle Trial Reports 37% Blinded Complete Remission In Venetoclax-failed R/R AML PatientsBenzinga · Jul 31, 2026, 12:10 PM
Moleculin Biotech shares are trading lower. The company announced a best‑efforts public offering of stock and warrants, including pre‑funded options to cap ownership.Benzinga · Jul 29, 2026, 6:57 PM
Moleculin CEO Highlights Preliminary Unblinded Efficacy Results From First 45 Patients Enrolled In Part A Of Pivotal Phase 2/3 MIRACLE Trial Evaluating Annamycin In R/R AML During Investor SegmentBenzinga · Jul 6, 2026, 12:50 PM
Why is Moleculin Stock Falling Today?Benzinga · Jun 30, 2026, 6:05 PM
Moleculin Biotech Announces Its Data From Phase 2/3 MIRACLE Study For Both Annamycin Treatment Arms Shows Efficacy; Composite Complete Remission Reaches 50%, 57% In Respective ArmsBenzinga · Jun 30, 2026, 12:40 PM
Moleculin Biotech Enrolls 45th Participant In Its Pivotal Phase 2B/3 MIRACLE Study Of Annamycin In Combination With Cytarabine To Treat Relapsed Or Refractory Acute Myeloid LeukemiaBenzinga · Jun 4, 2026, 12:55 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock